Literature DB >> 6499345

Chronopharmacokinetic study with prolonged infusion of midazolam.

U Klotz, I W Reimann.   

Abstract

Physiological and temporal variation in the disposition of midazolam has been reported. In order to delineate the underlying mechanisms of these alterations, we infused in 5 healthy male volunteers for 26 hours midazolam at a rate of 0.025 mg/kg/h preceded by a bolus of 0.05 mg/kg. Thus, steady-state conditions were rapidly achieved. Plasma levels of midazolam were monitored on a 2-hourly basis during this period. In addition, the pharmacodynamic response to the new sedative/hypnotic benzodiazepine was characterised by a pencil tracking test, sedation index formed from visual analogue scales, and choice reaction time. In all subjects, small (4 to 16%) but clinically irrelevant fluctuations of steady-state plasma concentrations around 45 ng/ml were observed. During the night-time (11pm to 7am) plasma concentrations were slightly (p = 0.074) higher than during the daytime. Total plasma clearance varied from 563 to 823 ml/min. Plasma protein binding of midazolam was time independent. Since in only 1 of 5 subjects was a circadian rhythm observed, fluctuations in plasma midazolam concentrations under controlled and constant conditions are probably not of clinical significance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6499345     DOI: 10.2165/00003088-198409050-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  21 in total

1.  Temporal variations in acetaminophen and phenacetin half-life in man.

Authors:  C A Shively; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Clinical, electroencephalographic, and pharmacokinetic studies of a water-soluble benzodiazepine, midazolam maleate.

Authors:  C R Brown; F H Sarnquist; C A Canup; T A Pedley
Journal:  Anesthesiology       Date:  1979-05       Impact factor: 7.892

3.  A water-soluble benzodiazepine, RO21-3981, for induction of anesthesia.

Authors:  R J Fragen; F Gahl; N Caldwell
Journal:  Anesthesiology       Date:  1978-07       Impact factor: 7.892

4.  Chronopharmacokinetics of dipyridamole.

Authors:  A Markiewicz; K Semenowicz; J Korczynska; A Czachowska
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-05

5.  CSF penetration and pharmacokinetics of midazolam.

Authors:  S Sjövall; J Kanto; J J Himberg; M Hovi-Viander; M Salo
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Chronopharmacokinetic study of a prolonged release form of indomethacin.

Authors:  P Guissou; G Cuisinaud; G Llorca; E Lejeune; J Sassard
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Midazolam kinetics.

Authors:  H Allonen; G Ziegler; U Klotz
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

8.  The pharmacokinetics of midazolam in man.

Authors:  M T Smith; M J Eadie; T O Brophy
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

9.  Physiological and pharmacological variability in estimated hepatic blood flow in man.

Authors:  T K Daneshmend; L Jackson; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

10.  Physiologic and temporal variation in hepatic elimination of midazolam.

Authors:  U Klotz; G Ziegler
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

View more
  11 in total

1.  Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping.

Authors:  Joseph D Ma; Anne N Nafziger; William Mylott; David B Haughey; Mario L Rocci; Joseph S Bertino
Journal:  Br J Clin Pharmacol       Date:  2008-12-12       Impact factor: 4.335

Review 2.  Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil.

Authors:  R Amrein; W Hetzel
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

3.  Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state.

Authors:  J Handel; G Ziegler; A Gemeinhardt; H Stuber; C Fischer; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

Review 4.  Chronopharmacokinetics of ciclosporin and tacrolimus.

Authors:  Massimo Baraldo; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Pharmacokinetics of the newer benzodiazepines.

Authors:  P D Garzone; P D Kroboth
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

6.  Development of midazolam sublingual tablets: in vitro study.

Authors:  P Odou; C Barthelemy; H Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

7.  Lack of accumulation of midazolam in plasma and lipoprotein fractions during intravenous lipid infusions in patients on artificial respiration.

Authors:  I Walter-Sack; J X de Vries; J Rudi; R Conradi; M Kohlmeier; B Kohl; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients.

Authors:  J Scholz; H Bause; M Schulz; U Klotz; D R Krishna; S Pohl; J Schulte am Esch
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

Review 9.  Clinical pharmacology of midazolam in infants and children.

Authors:  J L Blumer
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

Review 10.  Chronopharmacology of anti-convulsive therapy.

Authors:  Sriram Ramgopal; Sigride Thome-Souza; Tobias Loddenkemper
Journal:  Curr Neurol Neurosci Rep       Date:  2013-04       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.